行情

BIIB

BIIB

生物基因
NASDAQ

实时行情|Nasdaq Last Sale

301.21
-10.18
-3.27%
盘后: 299.71 -1.5 -0.50% 19:27 04/07 EDT
开盘
314.94
昨收
311.39
最高
319.60
最低
299.61
成交量
245.78万
成交额
--
52周最高
374.99
52周最低
215.78
市值
524.30亿
市盈率(TTM)
9.57
分时
5日
1月
3月
1年
5年

分析师评级

34位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BIIB价格均价为334.83,最高价位420.00,最低价为245.00。

EPS

BIIB 新闻

更多
  • FDA extends action date for Roche's risdiplam for spinal muscular atrophy
  • Seeking Alpha - Article · 6小时前
  • Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing
  • MotleyFool.com · 16小时前
  • Boston hotels may face stigma due to coronavirus-linked Biogen meeting
  • American City Business Journals · 1天前
  • GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln
  • Reuters · 1天前

所属板块

制药
-1.43%
制药与医学研究
-1.62%

热门股票

代码
价格
涨跌幅

BIIB 简况

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
展开

微牛提供Biogen Inc(NASDAQ-BIIB)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BIIB股票新闻,以帮助您做出投资决策。